CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

buparlisib

Small moleculeexperimental

Buparlisib is an experimental anti-cancer medication. It is a small molecule orally-available pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. Buparlisib was under investigation as a treatment for advanced breast cancer but was abandoned due to negative results. It is still under investigation as a potential treatment for head and neck squamous cell carcinoma (HNSCC). — Wikipedia

Clinical trial activity

90 trials · 58 clinical orgs · 0 marketing orgs

Phase 1
52
Phase 2
45
Phase 3
4
Phase 4
0

Earliest trial started Nov 1, 2008 (NCT01068483)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1
Mol. weight
410.4 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bkm120
  • bkm120
  • bkm120
  • bkm 120
  • bkm 120
  • bkm-120
  • bkm-120
  • bkm120-nx
  • bkm120-nx
  • bmk120
  • buparlisib
  • buparlisib
  • buparlisib
  • buparlisib
  • buparlisib
  • nvp-bkm120
  • nvp-bkm120
  • nvp-bkm120

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06081257N/AOct 15, 2023Zhejiang University
NCT04975958Phase 1Sep 7, 2021Adlai Nortye Biopharma Co., Ltd.
NCT04338399Phase 3Jul 31, 2020Adlai Nortye Biopharma Co., Ltd.
NCT02756247Phase 1May 1, 2016Cornell University, Janssen Pharmaceutica NV, Novartis
NCT02614508Phase 1Jan 1, 2016Emory University, Novartis
NCT01613677Phase 2Nov 1, 2015Novartis
NCT01971489Phase 1Sep 1, 2015National Cancer Institute (NCI), State University of New York, Buffalo
NCT02452294Phase 2Jul 1, 2015Technical University of Dresden, University of Tuebingen
NCT02303041N/AFeb 1, 2015National Cancer Institute (NCI), Stanford University
NCT02117817Phase 1Feb 1, 2015National Cancer Institute (NCI), Rutgers University
NCT02340780Phase 2Jan 30, 2015Canadian Cancer Trials Group, McGill University, Novartis
NCT02404844Phase 2Dec 1, 2014iOMEDICO AG, Novartis, University of Duisburg-Essen
NCT02301364Phase 2Nov 20, 2014Cornell University, Novartis
NCT02113878Phase 1Oct 1, 2014Harvard University, Novartis
NCT02487823Phase 1Oct 1, 2014Institut Paoli-Calmettes, Novartis
NCT02220855Phase 2Sep 1, 2014Indiana University, Novartis
NCT01953445Phase 2Aug 1, 2014Washington University in St. Louis
NCT02049541Phase 1Jul 1, 2014Novartis, Ohio State University
NCT02194049Phase 1Jul 1, 2014Novartis, University of California, Davis
NCT02159066Phase 2Jul 1, 2014Array BioPharma
Showing 20 of 90 trials
Page 1 / 5

Organizations

Research & Development (58)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovartisFor profit623132008
Harvard UniversityAcademic/Hospital8722011
National Cancer Institute (NCI)Government8032011
Cornell UniversityAcademic/Hospital5422011
SCRI Development InnovationsFor profit3312011
University of California, San FranciscoAcademic/Hospital3212011
Adlai Nortye Biopharma Co., Ltd.For profit2222020
Array BioPharmaFor profit2222011
Canadian Cancer Trials GroupAcademic/Hospital2212012
Emory UniversityAcademic/Hospital2212012
Institut Paoli-CalmettesAcademic/Hospital2222011
SOLTI Breast Cancer Research GroupAcademic/Hospital2112012
State University of New York, BuffaloAcademic/Hospital2212012
University of North Carolina at Chapel HillAcademic/Hospital2212011
University of Texas at HoustonAcademic/Hospital2122011
University of UtahAcademic/Hospital2112011
Washington University in St. LouisAcademic/Hospital2222011
ARCAGY-GINECOFor profit1112011
AstraZenecaFor profit1012012
Cancer Research UKAcademic/Hospital1012013
58 organizations
Page 1 / 3